CA2906771A1 - Compositions and methods for treating fungal and bacterial pathogens - Google Patents

Compositions and methods for treating fungal and bacterial pathogens

Info

Publication number
CA2906771A1
CA2906771A1 CA2906771A CA2906771A CA2906771A1 CA 2906771 A1 CA2906771 A1 CA 2906771A1 CA 2906771 A CA2906771 A CA 2906771A CA 2906771 A CA2906771 A CA 2906771A CA 2906771 A1 CA2906771 A1 CA 2906771A1
Authority
CA
Canada
Prior art keywords
seq
polypeptide
amino acid
acid sequence
isolated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2906771A
Other languages
English (en)
French (fr)
Inventor
Ashraf S. Ibrahim
Michael R. Yeaman
Scott G. Filler
John E. Edwards, Jr.
John P. Hennessey, Jr.
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novadigm Therapeutics Inc
Lundquist Institute for Biomedical Innovation at Harbor UCLA Medical Center
Original Assignee
Los Angeles Biomedical Research Institute at Harbor-Ucla Medical Center
Novadigm Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Los Angeles Biomedical Research Institute at Harbor-Ucla Medical Center, Novadigm Therapeutics Inc filed Critical Los Angeles Biomedical Research Institute at Harbor-Ucla Medical Center
Publication of CA2906771A1 publication Critical patent/CA2906771A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0002—Fungal antigens, e.g. Trichophyton, Aspergillus, Candida
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/104—Pseudomonadales, e.g. Pseudomonas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/21—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pseudomonadaceae (F)
    • C07K14/212—Moraxellaceae, e.g. Acinetobacter, Moraxella, Oligella, Psychrobacter
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/37—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi
    • C07K14/39—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi from yeasts
    • C07K14/40—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi from yeasts from Candida
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/14—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from fungi, algea or lichens
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/14—Fungi; Culture media therefor
    • C12N1/16—Yeasts; Culture media therefor
    • C12N1/165—Yeast isolates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/645—Fungi ; Processes using fungi
    • C12R2001/72—Candida
    • C12R2001/725—Candida albicans

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Wood Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Botany (AREA)
  • General Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CA2906771A 2013-03-15 2014-03-14 Compositions and methods for treating fungal and bacterial pathogens Abandoned CA2906771A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361789091P 2013-03-15 2013-03-15
US61/789,091 2013-03-15
PCT/US2014/028521 WO2014144211A2 (en) 2013-03-15 2014-03-14 Compositions and methods for treating fungal and bacterial pathogens

Publications (1)

Publication Number Publication Date
CA2906771A1 true CA2906771A1 (en) 2014-09-18

Family

ID=51538308

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2906771A Abandoned CA2906771A1 (en) 2013-03-15 2014-03-14 Compositions and methods for treating fungal and bacterial pathogens

Country Status (12)

Country Link
US (2) US10130691B2 (enExample)
EP (1) EP2968497B1 (enExample)
JP (2) JP6591961B2 (enExample)
CN (1) CN105407915A (enExample)
AU (1) AU2014227748B2 (enExample)
BR (1) BR112015022963A8 (enExample)
CA (1) CA2906771A1 (enExample)
EA (1) EA030005B1 (enExample)
MD (1) MD20150098A2 (enExample)
MX (1) MX2015012681A (enExample)
RU (1) RU2717306C2 (enExample)
WO (1) WO2014144211A2 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070077256A1 (en) 1999-11-19 2007-04-05 Los Angeles Biomedical Research Institute Pharmaceutical compositions and methods to vaccinate against disseminated candidiasis and other infectious agents
AU2014227748B2 (en) 2013-03-15 2019-02-14 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Compositions and methods for treating fungal and bacterial pathogens
WO2017155949A1 (en) 2016-03-09 2017-09-14 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Methods and kits for use in preventing and treating vulvovaginal candidiasis
CN112203684A (zh) * 2018-04-10 2021-01-08 海港医学中心洛杉矶生物医学研究所 耳念珠菌感染的治疗方法
US20220125651A1 (en) 2019-02-28 2022-04-28 Universidade Do Minho Antisense oligomers for controlling candida albicans infections
US20220354935A1 (en) * 2021-04-21 2022-11-10 Lundquist Institute For Biomedical Innovation At Harbor-Ucla Medical Center Vaccination against fungal epitopes to prevent inflammatory bowel diseases
WO2025248488A1 (en) * 2024-05-29 2025-12-04 Lundquist Institute For Biomedical Innovation At Harbor-Ucla Medical Center Compositions and methods for preventing and treating healthcare-associated candida auris infections with dual antigen vaccine

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1133829A (en) 1978-08-24 1982-10-19 National Research Development Corporation Pasteurellosis vaccines
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5622939A (en) 1992-08-21 1997-04-22 Alpha-Beta Technology, Inc. Glucan preparation
US5961970A (en) 1993-10-29 1999-10-05 Pharmos Corporation Submicron emulsions as vaccine adjuvants
AU2657495A (en) 1994-05-23 1995-12-18 Research And Development Institute, Inc. Candida albicans adhesin as a vaccine
US5668263A (en) 1994-12-16 1997-09-16 Smithkline Beecham Corporation Conserved yeast nucleic acid sequences
ATE200029T1 (de) 1995-06-07 2001-04-15 Pfizer In ovo impfung gegen coccidiose
CA2255669A1 (en) 1996-05-16 1997-11-20 The Texas A & M University System Collagen binding protein compositions and methods of use
US6747137B1 (en) 1998-02-13 2004-06-08 Genome Therapeutics Corporation Nucleic acid sequences relating to Candida albicans for diagnostics and therapeutics
US6248329B1 (en) 1998-06-01 2001-06-19 Ramaswamy Chandrashekar Parasitic helminth cuticlin nucleic acid molecules and uses thereof
US6703025B1 (en) 1998-08-31 2004-03-09 Inhibitex, Inc. Multicomponent vaccines
US20060083750A1 (en) 1999-11-19 2006-04-20 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Pharmaceutical compositions and methods to vaccinate against disseminated candidiasis
US7067138B1 (en) 1999-11-19 2006-06-27 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Pharmaceutical compositions and methods to vaccinate against disseminated candidiasis
US8541008B2 (en) 1999-11-19 2013-09-24 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Pharmaceutical compositions and methods to vaccinate against candidiasis
US20070077256A1 (en) 1999-11-19 2007-04-05 Los Angeles Biomedical Research Institute Pharmaceutical compositions and methods to vaccinate against disseminated candidiasis and other infectious agents
EP1450856B1 (en) 2001-09-14 2009-11-11 Cytos Biotechnology AG Packaging of immunostimulatory cpg into virus-like particles: method of preparation and use
CA2492823A1 (en) 2001-09-14 2003-03-27 Cytos Biotechnology Ag In vivo activation of antigen presenting cells for enhancement of immune responses induced by virus like particles
EP3698626A1 (en) 2001-11-30 2020-08-26 Amgen Fremont Inc. Transgenic animals bearing human ig lambda light chain genes
WO2003099325A1 (en) 2002-05-21 2003-12-04 Schering-Plough Ltd. Methods for the in vitro culture of sporozoea sp. and user thereof
US7241613B1 (en) * 2002-06-05 2007-07-10 Oscient Pharmaceuticals Corporation Identification of Candida cell surface proteins and their uses
AU2003290867A1 (en) 2002-11-12 2004-06-03 The Brigham And Women's Hospital, Inc. Methods and products for treating staphylococcal infections
CN1882360A (zh) 2003-11-21 2006-12-20 辉瑞产品公司 抗生素作为疫苗佐剂的用途
WO2005060713A2 (en) 2003-12-19 2005-07-07 Inhibitex, Inc. Method of inhibiting candida-related infections using donor selected or donor stimulated immunoglobulin compositions
GB0420466D0 (en) 2004-09-14 2004-10-20 Cassone Antonio Anti-glucan antibodies
WO2006036817A2 (en) * 2004-09-24 2006-04-06 Microbia, Inc. Fungal variants and uses thereof
CA2489194A1 (en) 2004-12-03 2006-06-03 Guilhem Janbon Polypeptides involved in candida biofilm formation and uses thereof
WO2007126813A2 (en) 2006-03-29 2007-11-08 Inhibitex, Inc. Cross-reactive monoclonal antibodies recognizing als family proteins
KR20080110908A (ko) 2006-04-17 2008-12-19 쉐링-프라우 리미티드 재조합의 약독화된 클로스트리듐 유기체 및 백신
EP2164511A1 (en) 2007-05-22 2010-03-24 Baylor College Of Medicine Immune complex vaccination as a strategy to enhance immunity in the elderly and other immune compromised populations
WO2009148895A1 (en) 2008-05-29 2009-12-10 Intervet International B.V. Coccidiosis vaccines
US20100150942A1 (en) 2008-12-03 2010-06-17 Cantor Thomas L Affinity purified human polyclonal antibodies and methods of making and using them
CN102481352A (zh) 2009-06-22 2012-05-30 惠氏有限责任公司 金黄色葡萄球菌抗原的免疫原性组合物
RU2015122387A (ru) * 2009-07-03 2015-10-27 Лос-Анжелес Биомедикал Ресёрч Институт Эт Харбор-Укла Медикал Центер Hyr1 в качестве мишени для активной и пассивной иммунизации против candida
CN103547296B (zh) * 2011-03-11 2016-08-17 非营利性组织佛兰芒综合大学生物技术研究所 用于抑制和检测蛋白质的分子和方法
WO2012163533A1 (en) 2011-06-01 2012-12-06 Eth Zurich T cell epitope of candida albicans
WO2013015831A1 (en) 2011-07-22 2013-01-31 Novadigm Therapeutics, Inc. Methods and compositions for vaccinating against staphylococcus aureus
US10160790B2 (en) 2011-09-14 2018-12-25 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center HYR1-derived compositions and methods of treatment using same
WO2014144222A2 (en) 2013-03-15 2014-09-18 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Compositions and methods of treating fungal and bacterial pathogens
AU2014227748B2 (en) 2013-03-15 2019-02-14 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Compositions and methods for treating fungal and bacterial pathogens
WO2014144024A1 (en) 2013-03-15 2014-09-18 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Hyr1 compositions and methods for treating fungal and bacterial pathogens
GB201503812D0 (en) 2015-03-06 2015-04-22 Univ Aberdeen Antibody molecules and uses thereof
WO2017155949A1 (en) 2016-03-09 2017-09-14 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Methods and kits for use in preventing and treating vulvovaginal candidiasis

Also Published As

Publication number Publication date
JP2016515516A (ja) 2016-05-30
EA201591808A1 (ru) 2016-02-29
MD20150098A2 (ro) 2016-02-29
EA030005B1 (ru) 2018-06-29
WO2014144211A2 (en) 2014-09-18
EP2968497A4 (en) 2016-11-30
WO2014144211A3 (en) 2015-11-19
RU2015144090A (ru) 2017-04-19
EP2968497B1 (en) 2020-08-12
MX2015012681A (es) 2018-05-17
BR112015022963A8 (pt) 2018-01-16
CN105407915A (zh) 2016-03-16
AU2014227748B2 (en) 2019-02-14
WO2014144211A8 (en) 2015-10-08
US20160030534A1 (en) 2016-02-04
JP6591961B2 (ja) 2019-10-16
RU2717306C2 (ru) 2020-03-19
US20190030141A1 (en) 2019-01-31
BR112015022963A2 (pt) 2017-11-14
AU2014227748A1 (en) 2015-10-08
JP2019110918A (ja) 2019-07-11
US10130691B2 (en) 2018-11-20
EP2968497A2 (en) 2016-01-20

Similar Documents

Publication Publication Date Title
US10130691B2 (en) Compositions and methods for treating fungal and bacterial pathogens
US10160790B2 (en) HYR1-derived compositions and methods of treatment using same
CN103998056B (zh) 用于接种抗金黄色葡萄球菌疫苗的方法和组合物
ES2313719T3 (es) Productos extracelulares abundantes y procedimiento de produccion y uso de los mismos.
JP2012532134A (ja) ＳｔｒｅｐｔｏｃｏｃｃｕｓＰｎｅｕｍｏｎｉａｅに対するワクチンおよび組成物
ES2371597T3 (es) Antígeno micobacteriano recombinante de tipo hemaglutinina de unión a la heparina (hbha) metilada.
WO2014144024A1 (en) Hyr1 compositions and methods for treating fungal and bacterial pathogens
US20160030533A1 (en) Compositions and methods of treating fungal and bacterial pathogens
CN105473156A (zh) 包含ama1和ron2的疫苗
CN109369809B (zh) 多表位抗原及其制备方法与在制备防治鹦鹉热衣原体感染的药物中的应用
WO2011067446A1 (es) Procedimiento de identificación de animales vacunados frente a brucella
US10590178B2 (en) Chimeric vaccine against fungal infections
US20060222650A1 (en) Broad spectrum pyrogenic antagonists and vaccines directed against pyrogenic exotoxins
US12409214B2 (en) Immunogenic antigens
US20190269771A1 (en) Peptide mimotope that induces an immune response against mycobacterium tuberculosis lipoarabinomannan (lam)
WO2026102355A1 (en) Multi-epitope antigenic polypeptides derived from acinetobacter baumannii and immunotherapeutic uses thereof
WO2023227563A1 (en) Protective staphylococcal exotoxin vaccine
EA047643B1 (ru) Слитые белки для противотуберкулезных вакцин

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20190325

FZDE Discontinued

Effective date: 20210831